Postmarketing Surveillance Study With MOBEC®

Boehringer Ingelheim4,760 enrolled

Overview

The aim of the study is to investigate * the indication for MOBEC in a dose of 15 mg per day * the treatments patients were receiving before switching to 15 mg MOBEC * how treatment with 15 mg is assessed compared with previous treatment * how effective and safe treatment with 15 mg MOBEC is considered

Study Type

OBSERVATIONAL

Enrollment

4,760

Conditions

Osteoarthritis

Interventions

MOBECDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * An indication for a treatment with 15 mg MOBEC of at least four weeks * the symptomatic short-term treatment of osteoarthritis * the symptomatic long-term treatment of rheumatoid arthritis (chronic polyarthritis); restriction: the recommended dose for long-term treatment of elderly patients is 7.5 mg) * the symptomatic treatment of ankylosing spondylitis Exclusion Criteria: * Treatment with MOBEC prior to the start of the study * Patients with any of the general or specific contraindications of MOBEC

Outcomes

Primary Outcomes

Nature and incidence of adverse drug reactions (ADR)

Time frame: up to week 8

Assessment of efficacy by physician on a 5-point scale

Time frame: up to week 8

Assessment of tolerability by physician on a 5-point scale

Time frame: up to week 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.